Added to YB: 2025-11-04
Pitch date: 2025-10-31
ARGX [bullish]
argenx SE
+6.26%
current return
Author Info
Lux Opes Research covers European companies. Lots of them. Sign up for the newsletter.
Company Info
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.
Market Cap
EUR 55.4B
Pitch Price
EUR 708.80
Price Target
N/A
Dividend
N/A
EV/EBITDA
72.01
P/E
38.93
EV/Sales
14.00
Sector
Biotechnology
Category
growth
Argenx (ARGX Belgium): executing like a market leader while widening the clinical moat
ARGX (quick overview): First $1B+ revenue quarter with strong uptake in myasthenia gravis & CIDP. Pre-filled syringe driving new patient starts. Positive operating profit shows scale benefits. Multi-billion cash balance provides optionality. Dense clinical calendar ahead in autoimmune indications. Platform proven, execution strong, early in monetizing broad mechanism.
Read full article (2 min)